US Vascular Access Device Market Will Surpass $2 Billion by 2022

March 13, 2014

Growing Adoption of Premium-Priced Safety and Antimicrobial Devices Will Support Revenue Growth, According to Findings from Decision Resources Group

BURLINGTON, Mass., March 13, 2014 /PRNewswire/ — Decision Resources Group finds that the United States vascular access device market will grow moderately to reach a value surpassing $2 billion by 2022. Market expansion will be supported by rising adoption of premium-priced safety and antimicrobial devices in the wake of concerns regarding needlestick safety and device sterility, respectively.


Other key findings from the report entitled US Markets for Vascular Access Devices 2014:

    --  PIVCs: Short peripheral intravenous catheters (PIVCs) will continue to
        represent the majority of unit sales and revenues, given their extremely
        frequent usage. However, the low cost of these products will result in
        disproportionately lower short PIVC revenues in relation to unit
    --  PICC: The recent emergence of tip positioning systems has dramatically
        improved the ease of peripherally inserted central catheter (PICC)
        placement. These systems, which incorporate guidance and placement
        confirmation technologies, have supported a rising number of PICC
        placements being performed by nurses.
    --  Teleflex Medical: Most recently, competitors such as Teleflex Medical
        have begun offering kits and trays for PICCs, central venous catheters
        and implantable ports that are specifically designed to promote
        sterility and to help health care providers comply with safety
        guidelines. These kits are more extensive than standard kits and include
        detailed step-by-step instructions for proper use.
    --  Becton, Dickinson and Company and C.R. Bard: Although Becton, Dickinson
        and Company only competes in the short PIVC market, this company holds
        significant market share due to the sheer size of this segment.
        Conversely, C. R. Bard maintains its strong position by offering devices
        in many segments. Combined, these two companies represented almost half
        of the total vascular access device market by revenue share in 2013.

Comments from Decision Resources Group Analyst Jonathan Sawatsky:

    --  "Arteriovenous graft manufacturers are developing new synthetic surgical
        grafts that can be cannulated for dialysis much sooner than
        previous-generation grafts, reducing the need for acute and chronic
        dialysis catheters while patients are awaiting graft maturity. These
        devices will limit dialysis catheter unit sales in the future,
        especially as uptake becomes more widespread."
    --  "Recently approved antithrombogenic devices, such as BioFlo PICCs and
        implantable ports by AngioDynamics and Nylus PICCs by Teleflex Medical,
        incorporate antithrombogenic polymers into their structure; unlike
        previous coated devices intended to reduce thrombus formation, the
        antithrombogenicity of these new devices will not dissipate over time.
        Consequently, there is potential for strong adoption of these devices
        pending positive data supporting their safety and effectiveness in
        clinical practice."

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group

Christopher Comfort



Logo – http://photos.prnewswire.com/prnh/20130103/MM36768LOGO

SOURCE Decision Resources Group

Source: PR Newswire

comments powered by Disqus